Intralenticular ozurdex® - One year later

Kathleen A. Regan, Charles R. Blake, Zachary L. Lukowski, Siva S.R. Iyer

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

Original languageEnglish (US)
Pages (from-to)590-594
Number of pages5
JournalCase Reports in Ophthalmology
Issue number3
StatePublished - Sep 14 2017
Externally publishedYes


  • Diabetic macular edema
  • Intralenticular dexamethasone implantation (Ozurdex®)
  • Nuclear sclerotic cataract

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intralenticular ozurdex® - One year later'. Together they form a unique fingerprint.

Cite this